PTGX

Protagonist Therapeutics (PTGX)

About Protagonist Therapeutics (PTGX)

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Details

Daily high

$85.05

Daily low

$81.55

Price at open

$82.11

52 Week High

$96.54

52 Week Low

$33.70

Market cap

5.3B

Dividend yield

0.00%

Volume

812,801

Avg. volume

828,110

P/E ratio

133.39

Protagonist Therapeutics News